# Evaluation of AP-002 in Patients With Solid Tumors

> **NCT04143789** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Altum Pharmaceuticals INC** · enrollment: 61 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** AP-002

## Key facts

- **NCT ID:** NCT04143789
- **Lead sponsor:** Altum Pharmaceuticals INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-27
- **Primary completion:** 2021-03
- **Final completion:** 2021-04
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2019-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143789, "Evaluation of AP-002 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04143789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*